

RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY

Aroa Biosurgery Ltd (ASX: ARX, 'AROA' or the 'Company') advises that James Agnew has tendered his resignation as Chief Financial Officer and Joint Company Secretary to pursue another opportunity.

James will remain with AROA until the end of November 2026 to effect a smooth and effective transition. Tracy Weimar will continue as joint Company Secretary, supported by James, until his departure.

The Company has commenced a recruitment process to appoint a new CFO and will provide an update to the market in due course.

AROA's CEO and Managing Director, Brian Ward, says *"Over the past 13 years, James has made a significant contribution to AROA's evolution from a small privately held company to a multinational business with global growth ambitions. He established the financial, governance and operational frameworks that supported the Company's transition to a listed entity, and lead AROA's ASX listing in 2020 and subsequent secondary capital raising. James managed the integration of the Endoform business after it was reacquired from Hollister and played a leadership role in guiding the Company through the COVID-19 pandemic as part of the executive team. His leadership has been instrumental in building the strong foundations that have positioned AROA for its next phase of growth. We thank James for his considerable contribution during this time and wish him every success in his new role."*

The Board also thanks James for his contributions over the past 13 years.

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'.
We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach.
Over 7 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.
Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com